{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:05:03Z","timestamp":1790687103952,"version":"4.1.0"},"reference-count":119,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Breast cancer is the most common malignancy among women. The HER2-low subgroup represents one of its prevalent subtypes; however, due to its unique characteristics, it presents challenges in diagnosis and treatment, complicating clinical management. This narrative review aims to synthesize evidence regarding the epidemiology, diagnosis, treatment, and prognosis of this subgroup. Methods: In this narrative review, following a search of PubMed, Web of Science, Scopus, and Google Scholar databases and the evaluation of 91 studies, findings were synthesized qualitatively and descriptively. Additionally, cohort studies, systematic reviews, and meta-analyses were utilized to explore associations and summarize prognostic trends. Results: The prevalence of HER2-low varied between 30% and 65% across different populations, with most studies reporting an association with hormone receptor (HR)-positive status and age over 50 years. Diagnostic challenges primarily stemmed from poor inter-pathologist agreement and laboratory variability. However, emerging technologies such as artificial intelligence (AI) and radiomics have shown promising results in diagnosis. Therapeutically, trastuzumab deruxtecan (T-DXd) demonstrated efficacy with response rates ranging from 21% to 62%; nevertheless, cross-resistance to antibody\u2013drug conjugates (ADCs) and high drug costs remain significant barriers. Patient prognosis and survival, beyond HER2 status, depended on factors such as HR status, Ki-67 index, lymph node involvement, and treatment response. Conclusions: HER2-low tumors constitute a distinct, highly prevalent subgroup with specific clinical features, necessitating differentiated diagnostic and therapeutic approaches. Despite the efficacy of T-DXd, obstacles such as intragroup heterogeneity, treatment resistance, high costs, and the lack of standardized diagnostic criteria persist. Therefore, attention to molecular profiling, standardization of diagnostic methods, and the development of cost-effective strategies are essential for equitable access to treatment.<\/jats:p>","DOI":"10.3390\/jcm15197559","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:09:25Z","timestamp":1790683765000},"page":"7559","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HER2-Low Breast Cancer: A Review of Epidemiology, Diagnostic Challenges, Targeted Therapies, and Clinical Outcomes"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8637-432X","authenticated-orcid":false,"given":"Maedeh","family":"Mirasheh","sequence":"first","affiliation":[{"name":"Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran 1419733171, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9955-4735","authenticated-orcid":false,"given":"Zahra","family":"Shahabinia","sequence":"additional","affiliation":[{"name":"Geriatric Health Research Center, Birjand University of Medical Sciences, Birjand 9717853577, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-9392","authenticated-orcid":false,"given":"Mai Abdel Haleem A.","family":"Abusalah","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4068-991X","authenticated-orcid":false,"given":"Afrooz","family":"Mazidimoradi","sequence":"additional","affiliation":[{"name":"Health Assistant Department, Shiraz University of Medical Sciences, Shiraz 7193711351, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-6771","authenticated-orcid":false,"given":"Leila","family":"Allahqoli","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Cyprus International University, Nicosia 99258, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7642-5214","authenticated-orcid":false,"given":"Hamid","family":"Salehiniya","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Health, Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand 9717853577, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-1713","authenticated-orcid":false,"given":"Do-Youn","family":"Lee","sequence":"additional","affiliation":[{"name":"College of General Education, Kookmin University, Seoul 02707, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"\u0141ukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., and Stanis\u0142awek, A. (2021). Breast Cancer\u2014Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies\u2014An Updated Review. Cancers, 13.","DOI":"10.3390\/cancers13174287"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.7314\/APJCP.2016.17.S3.43","article-title":"Incidence and Mortality and Epidemiology of Breast Cancer in the World","volume":"17","author":"Ghoncheh","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","unstructured":"International Agency for Research on Cancer (2025, February 24). Breast Cancer Cases and Deaths Are Projected to Rise Globally. Available online: https:\/\/www.iarc.who.int\/news-events\/breast-cancer-cases-and-deaths-are-projected-to-rise-globally\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40944-025-00977-3","article-title":"Global Trend of Breast Cancer Among Women Aged 55 and Older from 2010 to 2019: An Analysis by Socio-Demographic Index and Geographic Regions","volume":"23","author":"Rezaei","year":"2025","journal-title":"Indian J. Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Agostinetto, E., Rediti, M., Fimereli, D., Debien, V., Piccart, M., Aftimos, P., Sotiriou, C., and de Azambuja, E. (2021). HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. Cancers, 13.","DOI":"10.3390\/cancers13112824"},{"key":"ref_7","first-page":"151","article-title":"Epidemiological characteristics of and risk factors for breast cancer in the world","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Breast Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40644-026-01000-4","article-title":"A SHAP-interpretable XGBoost model: MRI-based intratumoral perfusion heterogeneity predicts HER2-zero, -low, and -positive ternary expression status in breast cancer","volume":"26","author":"Wang","year":"2026","journal-title":"Cancer Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/14796694.2026.2617853","article-title":"Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+\/HER2-low breast cancer","volume":"22","author":"Shin","year":"2026","journal-title":"Future Oncol."},{"key":"ref_10","first-page":"e103076","article-title":"NeoProspect HER2-low: Response and Prognosis After Neoadjuvant Treatment in Patients with HER2-low Breast Cancer","volume":"18","author":"Couto","year":"2026","journal-title":"Cureus"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Liang, H., Zhu, Z., and Kong, F. (2026). Trastuzumab deruxtecan in advanced breast cancer: A real-world study of efficacy and safety in Chinese cohort with HER2-positive and HER2-low expression. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1758757"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Emiro\u011flu, M., Kelten Talu, E.C., Karaali, C., \u00dcnal, O., and Erdo\u011fan, M. (2026). Comparison of Stromal Tumor-Infiltrating Lymphocyte (sTIL) Levels and Clinicopathological Features in Neoadjuvant-Naive HER2-Low and HER2-Negative Primary Breast Cancers. Medicina, 62.","DOI":"10.3390\/medicina62050826"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101006","DOI":"10.1016\/j.modpat.2026.101006","article-title":"Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort","volume":"39","author":"Denkert","year":"2026","journal-title":"Mod. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"106136","DOI":"10.1016\/j.labinv.2026.106136","article-title":"Immunohistochemical Assay Variability and HER2-low Breast Cancer Detection: A Laboratory Comparison in the Netherlands","volume":"106","author":"Kain","year":"2026","journal-title":"Lab. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/JCMA.0000000000001376","article-title":"Clinical presentations and prognostication of HER2-low and HER2-zero early breast cancer in Taiwan","volume":"89","author":"Chen","year":"2026","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sun, W., Hou, X., Yang, Z., Li, G., Zhang, L., Wang, Q., He, X., Zhang, X., Liu, L., and He, C. (2026). Clinicopathological Characteristics, Prognosis, and Survival of HER2-Low Breast Cancer Patients Based on a Retrospective Cohort Study of 14,642 Patients. Cancers, 18.","DOI":"10.3390\/cancers18101637"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4132\/jptm.2025.10.22","article-title":"Prevalence of HER2-ultralow breast cancer in South Korea: A multicenter study by reassessment of HER2-zero cases","volume":"60","author":"Kim","year":"2026","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17588359251353083","DOI":"10.1177\/17588359251353083","article-title":"Clinicopathological and molecular significance of HER2-low expression in Asian women with triple-negative breast cancer","volume":"17","author":"Yang","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104817","DOI":"10.1016\/j.breast.2026.104817","article-title":"Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4\/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study","volume":"88","author":"Pontolillo","year":"2026","journal-title":"Breast"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/tbcr-25-54","article-title":"Prognostic value of RecurIndex in differentiating HER2-low from HER2-negative early-stage breast cancer: A comprehensive clinicopathologic and molecular analysis in Chinese patients","volume":"7","author":"Zhang","year":"2026","journal-title":"Transl. Breast Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.3802\/jgo.2026.37.e86","article-title":"Evaluation of HER2 status in endometrial carcinoma using endometrial, gastric, and breast cancer criteria: Focus on HER2-low","volume":"37","author":"Yoon","year":"2026","journal-title":"J. Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4132\/jptm.2025.11.07","article-title":"Correlation between HER2 gene copy number and immunohistochemistry categories in HER2-negative breast cancer: Diagnostic utility for differentiating HER2-null, ultralow, and low tumors","volume":"60","author":"Kim","year":"2026","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e70085","DOI":"10.1002\/cncy.70085","article-title":"High accuracy in detecting HER2-low status in FNA of primary and metastatic breast cancer","volume":"134","author":"Cozzolino","year":"2026","journal-title":"Cancer Cytopathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1535-7163.MCT-25-0875","article-title":"Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumours","volume":"25","author":"Bashi","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zou, Y., Zhao, B., Mao, Y., Lv, M., Wang, Y., Su, X., Zhang, Z., Wu, J., and Wang, Q. (2025). A radiomic model leveraging conventional and Hessian matrix-based radiomic features from DCE-MRI for predicting efficacy of neoadjuvant chemotherapy in patients with HER2-low breast cancer. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1639977"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s43018-026-01181-8","article-title":"First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: Multicenter, open-label, phase 1b\/2 BEGONIA platform trial","volume":"7","author":"Schmid","year":"2026","journal-title":"Nat. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.21037\/tbcr-25-8","article-title":"Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses","volume":"6","author":"Wu","year":"2025","journal-title":"Transl. Breast Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17588359251318853","DOI":"10.1177\/17588359251318853","article-title":"Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: A multicenter, observational, real-world study","volume":"17","author":"Sang","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1111\/cas.70181","article-title":"Efficacy and Safety of T-DXd in HER2+ and Low\/Zero Metastatic BCBM: A Retrospective Multicenter Real-World Study","volume":"116","author":"Zhou","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Soares Miranda, L., Sousa, M.J., Martins Braga, M., Couto, M., Vieira Fernandes, I., Abreu, F., Eiriz, I., Lopes Fernandes, C., Fonseca Marques, A., and Marques, M.T. (2025). Trastuzumab Deruxtecan in Previously Treated HER2-Low Metastatic Breast Cancer: Real-World Multicentric Study in the Portuguese Population. Cancers, 17.","DOI":"10.3390\/cancers17121911"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4132\/jptm.2026.01.08","article-title":"HER2-low and ultralow breast cancer: Interobserver challenges and lessons from a consensus study","volume":"60","author":"Koh","year":"2026","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13000-025-01624-3","article-title":"Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff: HER2 IHC scoring concordance in breast cancer","volume":"20","author":"Vandenberghe","year":"2025","journal-title":"Diagn. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e70051","DOI":"10.1002\/2056-4538.70051","article-title":"Inter-rater agreement of HER2-low scores between expert breast pathologists and the Visiopharm digital image analysis application (HER2 APP, CE2797)","volume":"11","author":"Parry","year":"2025","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41523-021-00343-4","article-title":"Evolution of HER2-low expression from primary to recurrent breast cancer","volume":"7","author":"Miglietta","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.4143\/crt.2022.1633","article-title":"Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy","volume":"55","author":"Ma","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"104572","DOI":"10.1016\/j.breast.2025.104572","article-title":"HER2 testing in multifocal\/multicentric breast cancer: Should all foci be tested in the context of HER2-low and HER2-ultralow?","volume":"84","author":"Wu","year":"2025","journal-title":"Breast"},{"key":"ref_38","first-page":"1","article-title":"Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4\/6 inhibitors and hormone therapy","volume":"14","author":"Sottotetti","year":"2025","journal-title":"Drugs Context"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/noae163","article-title":"Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival","volume":"27","author":"Pereslete","year":"2025","journal-title":"Neuro Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1007\/s12094-025-04106-6","article-title":"Is the risk of brain metastasis and prognosis different in HER2-low breast cancer?","volume":"28","author":"Culha","year":"2026","journal-title":"Clin. Transl. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1007\/s12325-025-03426-x","article-title":"Addressing the Challenges in the Identification of HER2-Low and Ultralow Breast Cancer in Asia: A Delphi Consensus","volume":"43","author":"Shah","year":"2026","journal-title":"Adv. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104721","DOI":"10.1016\/j.breast.2026.104721","article-title":"Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States","volume":"86","author":"Modi","year":"2026","journal-title":"Breast"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.21037\/tbcr-25-53","article-title":"Efficacy and safety of T-DXd in patients with HER2-positive and HER2-low metastatic breast cancer: A real-world study","volume":"7","author":"Lu","year":"2026","journal-title":"Transl. Breast Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e2500814","DOI":"10.1200\/PO-25-00814","article-title":"Real-World Study Assessing Characteristics and Treatment Patterns of Patients with Human Epidermal Growth Factor Receptor 2 Immunohistochemistry 0 and Human Epidermal Growth Factor Receptor 2-Low Stage IV Breast Cancer: A Multicenter Retrospective Study","volume":"10","author":"Tan","year":"2026","journal-title":"JCO Precis. Oncol."},{"key":"ref_45","first-page":"101204","article-title":"Characterization of real-world clinical and pathological differences between HER2-0 and HER2-low localized breast cancer","volume":"47","author":"Juhanoja","year":"2026","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Bedir, \u015e., Kapagan, T., \u00c7akan Demirel, B., Tokocin, M., Y\u0131ld\u0131r\u0131m, \u00c7., Ta\u015f, S., Bozkaya, Y., Oyman, A., Bulut, N., and Erdem, G.U. (2026). Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4\/6 Inhibitors. J. Clin. Med., 15.","DOI":"10.3390\/jcm15051898"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/jmri.29447","article-title":"Preoperative Differentiation of HER2-Zero and HER2-Low from HER2-Positive Invasive Ductal Breast Cancers Using BI-RADS MRI Features and Machine Learning Modeling","volume":"61","author":"Zhou","year":"2025","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Singareeka Raghavendra, A., Liu, D.D., Damodaran, S., Pasyar, S., Shen, Y., Mouabbi, J.A., Barcenas, C.H., Hunt, K.K., and Tripathy, D. (2026). Prevalence and Outcomes of HER2-Low Versus HER2-0 Status in Patients with Metastatic Breast Cancer. Cancers, 18.","DOI":"10.3390\/cancers18020253"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e03925","DOI":"10.1002\/advs.202503925","article-title":"A Dynamic Contrast-Enhanced MRI-Based Vision Transformer Model for Distinguishing HER2-Zero, -Low, and -Positive Expression in Breast Cancer and Exploring Model Interpretability","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_50","first-page":"863","article-title":"Efficacy of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer: A Real-World Retrospective Cohort Study in China","volume":"17","author":"Yan","year":"2025","journal-title":"Breast Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13058-025-02058-x","article-title":"Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: An international multicentric study","volume":"27","author":"Nguyen","year":"2025","journal-title":"Breast Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104584","DOI":"10.1016\/j.breast.2025.104584","article-title":"Clinical and molecular characteristics of HER2-low triple-negative breast cancer: Insights from multi-omics analysis","volume":"84","author":"Yang","year":"2025","journal-title":"Breast"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Rodrigues, P.R., Lopes-Concei\u00e7\u00e3o, L., Sousa, V., Coutada, A., Bento, M.J., Coimbra, N., Leal, C., Pereira, D., and Magalh\u00e3es Ferreira, A. (2025). The clinicopathological characteristics, oncologic outcomes and costs of \u201cHER2-low\u201d early breast cancer compared to HER2-zero and HER2-positive: A single-centre retrospective analysis. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1579602"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e13086","DOI":"10.1002\/advs.202513086","article-title":"Proteogenomic Characterization Reveals Subtype-Specific Therapeutic Potential for HER2-Low Breast Cancer","volume":"13","author":"Xu","year":"2026","journal-title":"Adv. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"603190","DOI":"10.2147\/IJGM.S603190","article-title":"Real-World Safety of Trastuzumab Deruxtecan in Patients with HER2-Positive and HER2-Low Metastatic Breast Cancer in Saudi Arabia: A Retrospective Cohort Study","volume":"19","author":"Alhuthali","year":"2026","journal-title":"Int. J. Gen. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Carvalho, E., Brand\u00e3o, A., Schmitt, F., and Vale, N. (2026). MicroRNA-Gene Networks Distinguish Hormone Receptor Status in HER2-Low Breast Cancer: An Integrative Transcriptomic Analysis. Genes, 17.","DOI":"10.3390\/genes17030305"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Cai, S., Yu, S., Zhou, Q., Kuang, F., Rao, L., Fang, Z., Zheng, X., Shi, Y., and Li, J. (2026). Tumour microenvironment and HER2-low status dictate response and resistance to anthracycline-taxane chemotherapy in premenopausal TNBC: A retrospective multicohort study. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1752328"},{"key":"ref_58","first-page":"101276","article-title":"Effectiveness of pegylated liposomal doxorubicin (Caelyx\u00ae) monotherapy in patients with metastatic HER2-low breast cancer: A monocentric retrospective study","volume":"48","author":"Boudier","year":"2026","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_59","first-page":"101112","article-title":"Clinical characteristics and survival outcomes of young women with luminal HER2-low and HER2-ultralow breast cancer","volume":"46","author":"Mohar","year":"2026","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhan, T., Leng, Y., Liu, X., Dai, J., and Gong, L. (2026). Differentiation of HER2-Zero, -Low, and -Overexpressing Breast Cancer Using Amide Proton Transfer-Weighted Magnetic Resonance Imaging: A Single-center Preliminary Study. Acad. Radiol.","DOI":"10.1016\/j.acra.2026.05.015"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/CM9.0000000000003942","article-title":"Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status","volume":"139","author":"Yang","year":"2026","journal-title":"Chin. Med. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13000-025-01632-3","article-title":"Redefining therapeutic landscapes: Clinicopathological insights into low and ultra-low HER2 expression in male breast cancer","volume":"20","author":"Shang","year":"2025","journal-title":"Diagn. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4048\/jbc.2024.0223","article-title":"Differences in HER2-0 and HER2-low Breast Cancer: Androgen Receptor and Programmed Death Ligand 1 as Predictive Factors","volume":"28","author":"Zhang","year":"2025","journal-title":"J. Breast Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"18758592261427515","DOI":"10.1177\/18758592261427515","article-title":"The impact of HER2 low positivity in hormone receptor-positive, HER2-negative breast cancer treated with neoadjuvant chemotherapy","volume":"43","author":"Ersoy","year":"2026","journal-title":"Cancer Biomark."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Bagegni, N.A., Giridhar, K.V., and Stewart, D. (2025). HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers. Cancers, 17.","DOI":"10.3390\/cancers17244021"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Shaaban, A.M., Kaur, T., and Provenzano, E. (2025). HER2-Low Breast Cancer\u2014Current Knowledge and Future Directions. Medicina, 61.","DOI":"10.3390\/medicina61040644"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"103096","DOI":"10.1016\/j.ctrv.2026.103096","article-title":"Integrating antibody-drug conjugates into the management of early breast cancer","volume":"144","author":"Alda","year":"2026","journal-title":"Cancer Treat. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Jacot, W., Maran-Gonzalez, A., Massol, O., Sorbs, C., Mollevi, C., Guiu, S., Boissi\u00e8re-Michot, F., and Ramos, J. (2021). Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers. Cancers, 13.","DOI":"10.3390\/cancers13236059"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40001-024-02188-6","article-title":"Evaluating dynamic contrast-enhanced MRI for differentiating HER2-zero, HER2-low, and HER2-positive breast cancers in patients undergoing neoadjuvant chemotherapy","volume":"30","author":"Hu","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8387","DOI":"10.21037\/qims-24-428","article-title":"Preoperatively predicting human epidermal growth factor receptor 2-low expression in breast cancer using neural network model based on multiparameter magnetic resonance imaging","volume":"14","author":"Zhao","year":"2024","journal-title":"Quant. Imaging Med. Surg."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Yin, L., Zhang, Y., Wei, X., Shaibu, Z., Xiang, L., Wu, T., Zhang, Q., Qin, R., and Shan, X. (2024). Preliminary study on DCE-MRI radiomics analysis for differentiation of HER2-low and HER2-zero breast cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1385352"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.21037\/qims-24-976","article-title":"Development of a prediction model for HER2 low breast cancer using quantitative intra- and peri-tumoral heterogeneity and MRI features on high-spatial resolution ultrafast DCE-MRI","volume":"15","author":"Luo","year":"2025","journal-title":"Quant. Imaging Med. Surg."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"R150","DOI":"10.1088\/0031-9155\/61\/13\/R150","article-title":"Applications and limitations of radiomics","volume":"61","author":"Yip","year":"2016","journal-title":"Phys. Med. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: Images Are More than Pictures, They Are Data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/14796694.2024.2434388","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: A plain language summary of the DESTINY-Breast04 study","volume":"21","author":"Modi","year":"2025","journal-title":"Future Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/1078-0432.CCR-25-0874","article-title":"DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer","volume":"32","author":"Jhaveri","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.32604\/or.2025.065029","article-title":"Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis","volume":"33","author":"Zhang","year":"2025","journal-title":"Oncol. Res."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Qu, F., Lu, R., Wu, X., Liu, Q., Zha, M., Li, H., Yuan, Y., Han, Z., Cai, D., and Huang, X. (2024). Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: A multicenter, real-world study. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1435485"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1245\/s10434-023-14800-w","article-title":"Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?","volume":"31","author":"Polidorio","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5597051","DOI":"10.1155\/ijbc\/5597051","article-title":"Clinical Outcomes of HER2-Low Versus HER2-Zero in HR-Positive Metastatic Breast Cancer Treated with Endocrine Therapy with or Without CDK4\/6 Inhibitors: A Multicenter Retrospective Study","volume":"2025","author":"Susiriwatananont","year":"2025","journal-title":"Int. J. Breast Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"105186","DOI":"10.1016\/j.ebiom.2024.105186","article-title":"Clinical efficacy of CDK4\/6 inhibitor plus endocrine therapy in HR-positive\/HER2-0 and HER2-low-positive metastatic breast cancer: A secondary analysis of PALOMA-2 and PALOMA-3 trials","volume":"105","author":"Li","year":"2024","journal-title":"eBioMedicine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e41082","DOI":"10.1097\/MD.0000000000041082","article-title":"First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis","volume":"103","author":"Li","year":"2024","journal-title":"Medicine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.breast.2021.08.016","article-title":"Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer","volume":"60","author":"Mutai","year":"2021","journal-title":"Breast"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"17588359241309169","DOI":"10.1177\/17588359241309169","article-title":"Predictive factors for complete pathologic response in luminal breast cancer: Impact of ki67 and HER2 low expression","volume":"16","author":"Miras","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Shao, Y., Guan, H., Luo, Z., Yu, Y., He, Y., Chen, Q., Liu, C., Zhu, F., and Liu, H. (2025). Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1459444"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13058-025-01969-z","article-title":"HER2-low status as a distinct breast cancer subtype: Myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+\/HER2-, WSG-PlanB, and WSG-ADAPT-TN","volume":"27","author":"Schmidt","year":"2025","journal-title":"Breast Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"17588359241290720","DOI":"10.1177\/17588359241290720","article-title":"Deciphering HER2-low breast cancer (BC): Insights from real-world data in early stage breast cancer","volume":"16","author":"Pous","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Park, W.K., Nam, S.J., Kim, S.W., Lee, J.E., Yu, J., Ryu, J.M., and Chae, B.J. (2023). The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15225361"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"16719","DOI":"10.1038\/s41598-023-43186-8","article-title":"Tumor characteristics and survival rate of HER2-low breast cancer patients: A retrospective cohort study","volume":"13","author":"Abbasvandi","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2340\/1651-226X.2024.41280","article-title":"Survival outcomes for HER2-low breast cancer: Danish national data","volume":"63","author":"Sode","year":"2024","journal-title":"Acta Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41598-025-31515-y","article-title":"Clinical characteristics and prognostic impact of HER2 low expression in breast cancer subtypes from a Brazilian real-world cohort","volume":"16","author":"Mattar","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Colak, R., Kapar, C., Degerli, E., Tacar, S.Y., Gemici, A.A., Gergerlioglu, N., Altinay, S., and Yilmaz, M. (2025). Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy. Medicina, 61.","DOI":"10.3390\/medicina61071168"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e70637","DOI":"10.1002\/cam4.70637","article-title":"Investigating HER2-Low in Early Breast Cancer: Prognostic Implications and Age-Related Prognostic Stratification","volume":"14","author":"Chen","year":"2025","journal-title":"Cancer Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1093\/oncolo\/oyad275","article-title":"HER2-Low Status Was Associated with Better Breast Cancer-Specific Survival in Early-Stage Triple-Negative Breast Cancer","volume":"29","author":"Ma","year":"2024","journal-title":"Oncologist"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Liu, J.J., Zhang, Y., Zhang, S.C., Liu, X., Wang, S.N., Liu, X.Y., and Zhang, J. (2024). Analysis of factors influencing the efficacy of NAC and prognosis between HER2-zero and HER2-low HR negative breast cancer. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1417271"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"197","DOI":"10.21037\/gs-22-747","article-title":"Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer","volume":"12","author":"Chen","year":"2023","journal-title":"Gland. Surg."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13058-021-01492-x","article-title":"Landscape of HER2-low metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry","volume":"23","author":"Gampenrieder","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10549-023-06927-x","article-title":"HER-2 low status in early-stage invasive lobular carcinoma of the breast: Associated factors and outcomes in an institutional series","volume":"199","author":"Rothschild","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Takada, K., Kashiwagi, S., Nishikawa, M., Kochi, A., Watanabe, C., Kinoshita, H., Ogisawa, K., Shibutani, M., and Morisaki, T. (2025). Differences in Sentinel lymph node biopsy outcomes and prognosis between HER2-low and HER2-zero breast cancer. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14970-8"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients with HER2-Low-Expressing Advanced Breast Cancer: Results from a Phase Ib Study","volume":"38","author":"Modi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e2400641","DOI":"10.1200\/PO-24-00641","article-title":"Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients with Breast Cancer: A Retrospective Cohort Study","volume":"9","author":"Fan","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Farah, E., Carbonell, C., Boyne, D.J., Brenner, D.R., Henning, J.W., Moldaver, D., Shokar, S., and Cheung, W.Y. (2024). Treatment Patterns and Health Outcomes among Patients with HER2 IHC0\/-Low Metastatic or Recurrent Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16030518"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12957-025-03962-4","article-title":"Differences in survival outcomes between HER2-low and HER2-zero breast cancer across heterogeneous HR expression patterns: A real-world study","volume":"23","author":"Zeng","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1097\/CM9.0000000000002831","article-title":"A multicenter study of the clinicopathological characteristics and a risk prediction model of early-stage breast cancer with hormone receptor-positive\/human epidermal growth factor receptor 2-low expression","volume":"136","author":"Xin","year":"2023","journal-title":"Chin. Med. J."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Sun, T., Wang, T., Li, X., Wang, H., and Mao, Y. (2023). Tumor-infiltrating lymphocytes provides recent survival information for early-stage HER2-low-positive breast cancer: A large cohort retrospective study. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1148228"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Li, Y., Abudureheiyimu, N., Mo, H., Guan, X., Lin, S., Wang, Z., Chen, Y., Chen, S., Li, Q., and Cai, R. (2021). In Real Life, Low-Level HER2 Expression May Be Associated with Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.774577"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Xia, Y., Song, J., Zhang, H., Liu, S., and Luo, J. (2026). Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1857207"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.14740\/wjon2718","article-title":"Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates","volume":"17","author":"Zheng","year":"2026","journal-title":"World J. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"105179","DOI":"10.1016\/j.critrevonc.2026.105179","article-title":"Resistance mechanisms and post-trastuzumab deruxtecan (T-DXd) strategies in HER2+ and HER2-low breast cancer: From biology to clinical practice","volume":"221","author":"Wen","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: Pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low Breast Cancer: Pathological and Clinical Landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_114","first-page":"605985","article-title":"Artificial Intelligence-Driven Quantitative HER2 Scoring and Spatial Bystander Effect Modeling for ADC Response Stratification in HER2-Low Breast Cancer","volume":"18","author":"Liu","year":"2026","journal-title":"Breast Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41392-024-02047-0","article-title":"Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Zhan, M., Huang, Z., Xu, T., Xu, X., Zheng, H., and Wu, F. (2023). Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1049947"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"17588359231169983","DOI":"10.1177\/17588359231169983","article-title":"Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer","volume":"15","author":"Yang","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13058-025-01989-9","article-title":"Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis","volume":"27","author":"Chaves","year":"2025","journal-title":"Breast Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"121134","DOI":"10.1016\/j.cca.2026.121134","article-title":"Clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast Cancer: A systematic review and Meta-analysis","volume":"592","author":"Liu","year":"2026","journal-title":"Clin. Chim. Acta"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7559\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:46:05Z","timestamp":1790685965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":119,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197559"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197559","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}